Improving prognosis of glioblastoma in the 21st century: Who has benefited most?

BACKGROUND: Glioblastoma multiforme (GBM) is the most frequent primary brain tumor in adults. Temozolomide was rapidly incorporated into first‐line treatment following the publication of the pivotal European Organization for Research and Treatment of Cancer–National Cancer Institute of Canada phase...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2012-09, Vol.118 (17), p.4228-4234
Main Authors: Lawrence, Yaacov Richard, Mishra, Mark V., Werner‐Wasik, Maria, Andrews, David W., Showalter, Timothy N., Glass, Jon, Shen, Xinglei, Symon, Zvi, Dicker, Adam P.
Format: Article
Language:English
Subjects:
Age Factors
Aged
Biological and medical sciences
Brain Neoplasms - mortality
Brain Neoplasms - radiotherapy
Brain Neoplasms - surgery
Combined Modality Therapy
elderly
Female
glioblastoma
Glioblastoma - mortality
Glioblastoma - radiotherapy
Glioblastoma - surgery
glioma
health disparities
Humans
Income
Male
Medical sciences
Middle Aged
Neurology
Population Surveillance
Prognosis
radiation treatment
Survival Analysis
temozolomide
Time Factors
Tumors
Tumors of the nervous system. Phacomatoses
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: Glioblastoma multiforme (GBM) is the most frequent primary brain tumor in adults. Temozolomide was rapidly incorporated into first‐line treatment following the publication of the pivotal European Organization for Research and Treatment of Cancer–National Cancer Institute of Canada phase 3 trial in 2005. However, in the trial, enrollment was limited to younger patients with good performance status. Therefore, this study performed a population‐based survival analysis of patients with newly diagnosed GBM covering the period before and after the introduction of temozolomide. METHODS: Survival statistics and clinical and demographic variables were extracted from the Survival, Epidemiology and End Results Database for patients diagnosed with GBM from 2001 to 2007. Mean regional income for each patient was also collected. Survival was analyzed using the Kaplan‐Meier method and proportional hazard models. RESULTS: A total of 13,003 adult patients diagnosed with a GBM were identified. Prognostic variables included age
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.26685